Latest Regulatory Scrutiny News

Northern Minerals has applied to defer its 2025 AGM as it awaits regulatory review over potential foreign investment breaches, underscoring heightened scrutiny on shareholder compliance.

The Star Entertainment Group has secured crucial regulatory approvals to convert a $300 million strategic investment by Bally’s Corporation and Investment Holdings into equity, setting the stage for board changes and a path toward financial recovery.

Mayne Pharma’s acquisition by Cosette Pharmaceuticals faces a brief delay as FIRB extends its approval deadline, prompting a reschedule of the critical court hearing to November 23.

Bubs Australia Limited reported a solid FY25 with $102.5 million revenue and outlined ambitious FY26 guidance targeting up to $125 million, driven by overseas markets and strategic investments.

NexGen Energy has entered the final phase of federal regulatory approval for its flagship Rook I uranium project, marking a pivotal step toward construction and production. This follows over a decade of environmental assessments and provincial approvals.

Infomedia Ltd has announced a fully franked special dividend of 2.9 cents per share, payable in late November, linked to its pending acquisition by McQueen BidCo Pty Ltd.

TPG Telecom has successfully raised $300 million through its institutional reinvestment plan, issuing new shares at a discount to offset recent capital returns and strengthen its balance sheet. The plan faced adjustments due to a tragic incident and volatile market conditions.

Capricorn Metals Ltd has had its CMMO securities class suspended from ASX trading pending regulatory compliance, raising questions about the company’s next steps.

The Takeovers Panel has issued interim orders extending the deadline for Mayne Pharma's takeover scheme with Cosette Pharmaceuticals, preventing termination without consent and maintaining the status quo.

The Takeovers Panel has intervened in the Mayne Pharma and Cosette Pharmaceuticals scheme, issuing interim orders that extend the deal deadline and restrict termination rights to maintain the status quo.

Solvar Limited reported solid FY25 results with profit growth, a significant dividend hike, and a positive outlook for FY26 driven by loan originations and commercial lending expansion.

The Foreign Investment Review Board has extended its deadline for approving Mayne Pharma's acquisition by Cosette Pharmaceuticals, maintaining the current transaction timetable for now.